Lobbying client
HUMAN LONGEVITY, INC.
Genomics and cell therapy-based diagnostic and therapeutic company.
Filings
13
Filed by
1
Reported in-house
—
Reported by firms
$530,000
Reported lobbying by year
The larger of in-house and firm-reported each year, $ thousands
2015 to 2017
Filings
13 filings, newest first.
| Filing | Filed by | Amount |
|---|---|---|
|
3rd Quarter - Termination 3rd Quarter 2017
|
PODESTA GROUP, INC. | $40,000 reported |
|
2nd Quarter - Report 2nd Quarter 2017
|
PODESTA GROUP, INC. | $50,000 reported |
|
1st Quarter - Report 1st Quarter 2017
|
PODESTA GROUP, INC. | $50,000 reported |
|
4th Quarter - Report 4th Quarter 2016
|
PODESTA GROUP, INC. | $50,000 reported |
|
3rd Quarter - Report 3rd Quarter 2016
|
PODESTA GROUP, INC. | $50,000 reported |
|
2nd Quarter - Report 2nd Quarter 2016
|
PODESTA GROUP, INC. | $50,000 reported |
|
1st Quarter - Report 1st Quarter 2016
|
PODESTA GROUP, INC. | $50,000 reported |
|
2nd Quarter - Amendment 2nd Quarter 2015
|
PODESTA GROUP, INC. | $50,000 reported |
|
4th Quarter - Report 4th Quarter 2015
|
PODESTA GROUP, INC. | $50,000 reported |
|
3rd Quarter - Report 3rd Quarter 2015
|
PODESTA GROUP, INC. | $50,000 reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| PODESTA GROUP, INC. | 11 | $530,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Budget/Appropriations | BUD | 12 |
| Science/Technology | SCI | 12 |
| Medical/Disease Research/Clinical Labs | MED | 12 |
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.